Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor - Wikidata - wikimedia - TriplyDB

Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor

Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor

http://www.wikidata.org/entity/Q33597663

about

Akt and mTOR in B Cell Activation and Differentiation PRR5L degradation promotes mTORC2-mediated PKC-δ phosphorylation and cell migration downstream of Gα12 Targeting mTOR for the treatment of AML. New agents and new directions Targeting the mTOR kinase domain: the second generation of mTOR inhibitors Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy mTOR: from growth signal integration to cancer, diabetes and ageing mTOR signaling in growth control and disease New molecular targets in mantle cell lymphoma Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies mTOR-dependent cell survival mechanisms mTOR Signaling in Protein Translation Regulation: Implications in Cancer Genesis and Therapeutic Interventions Signal transduction in the chronic leukemias: implications for targeted therapies mTOR kinase inhibitors as potential cancer therapeutic drugs Effects of TORC1 Inhibition during the Early and Established Phases of Polycystic Kidney Disease A pyrrolo-pyrimidine derivative targets human primary AML stem cells in vivo mTOR-independent 4E-BP1 phosphorylation is associated with cancer resistance to mTOR kinase inhibitors.mTORC2 promotes type I insulin-like growth factor receptor and insulin receptor activation through the tyrosine kinase activity of mTOR Sustained proliferation in cancer: Mechanisms and novel therapeutic targets A comparison of Ku0063794, a dual mTORC1 and mTORC2 inhibitor, and temsirolimus in preclinical renal cell carcinoma models Resistance to mTOR kinase inhibitors in lymphoma cells lacking 4EBP1 PI3K and cancer: lessons, challenges and opportunities Constitutive reductions in mTOR alter cell size, immune cell development, and antibody production.Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer.Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells.A mechanism for synergy with combined mTOR and PI3 kinase inhibitors.Subconjunctival Palomid 529 in the treatment of neovascular age-related macular degeneration Rapalogs in viral cancers.PI3K and mTOR signaling pathways in cancer: new data on targeted therapies.Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.Zebrafish screen identifies novel compound with selective toxicity against leukemia.Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment.A critical role for mTORC1 in erythropoiesis and anemia.Extensive gene-specific translational reprogramming in a model of B cell differentiation and Abl-dependent transformation The evolution of the TOR pathway and its role in cancer.CD98 increases renal epithelial cell proliferation by activating MAPKs.Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor.mTOR attenuates the inflammatory response in cardiomyocytes and prevents cardiac dysfunction in pathological hypertrophy.Syrosingopine sensitizes cancer cells to killing by metformin mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms.A novel Bcr-Abl-mTOR-eIF4A axis regulates IRES-mediated translation of LEF-1

P2860

Q21131224-F932D1E6-C9DB-4395-A59A-59C613766B16 Q24323912-B3C487F2-FAA3-4795-A3E8-EB1C0292C567 Q24617223-3189172C-8BF8-4586-8D3E-254802092365 Q24622194-978C3C48-5501-45C3-88CF-3141CF82F233 Q24632296-A7D3308C-CBD5-4D9E-B844-406C09193177 Q24633662-A3B03FF2-D1CC-4235-9D1C-B52E8BF43EAB Q24634174-F29B3C20-4652-4FEB-BCF6-A7834FED800C Q26821766-AD783803-C9BD-4398-BCE6-A737782E4057 Q26829652-53A456F8-13E6-424E-91E4-D0D71B789ED1 Q26864688-FD6CA5E1-154F-4B00-A5C0-111BC67FD1CD Q27007511-BE31F529-2FEF-4A4D-B7E5-7F7C3CC10C98 Q27026031-1ACE7E85-C38F-457D-8AB3-85E82699E475 Q27027963-78F01CA7-57B0-4964-9991-2356FFFFF34D Q27320627-28141F1E-5F39-4280-A9FB-26D1CF4FE982 Q27684428-952E2ED8-6F62-4A93-9700-EDAC458EFC0B Q27851707-38CF03E3-5157-4A0B-9BAB-730985FB6F2E Q28270006-C934AFA4-C80F-4FED-9E0A-10E592F150AE Q28396388-D36063A4-5560-412B-8517-69BB8D7DE401 Q28485220-48C66FF8-13D3-456D-A87A-320282DD58E6 Q28540038-6105B21C-5385-4D23-82B1-3D44F7C6EE68 Q30080017-6E21307D-862A-4F75-9063-8B5739EA504B Q30498613-B867D25D-FC59-498F-B419-97930AB90011 Q30582030-471B131D-619A-4332-8D89-157005948884 Q34004994-84534579-5910-4EE0-B0CB-508BBAC7BE92 Q34062367-9425F893-5A6D-4B02-8161-AE2B64BA55EC Q34127531-B69DA640-53EC-4F4A-89BE-F80B7D22024D Q34160579-75927E9C-BD66-4A29-8A16-85E77D0CC7CD Q34164683-5728CF55-529D-4B81-8142-8194199E2995 Q34173253-3FF22FD7-72A9-4E09-8262-24D074182297 Q34227256-B5DBF2A2-FB92-4F3F-9115-0339CA199420 Q34260622-83BA8C31-6A5A-4B71-8A9F-3B141E6FF1C3 Q34263944-F71D1BC6-738F-4F48-B9DC-0FE87DEC0D6F Q34302309-31CE7EA9-E8D5-4D81-8E32-7F30399F147F Q34318188-F681056F-7D99-4015-826E-DAEB84F9CEA1 Q34328557-7AC6C191-4889-4BE2-9D22-FC89B923937A Q34374071-81698348-55AE-4C93-A864-58A8A5A814CD Q34426387-5A95E4D4-FF62-44E3-9BE2-366AF504593C Q34548130-FDBF6D05-00ED-4B9B-8EB6-5FAED24EB873 Q34575726-6E50E1AB-71C7-4F00-93A7-6FEBD1439CEC Q34589167-9F24A41C-0F4F-45CF-8D34-51A67A51E602

P2860

Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor

http://www.wikidata.org/entity/Q33597663

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor

@ast

Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor

@en

type

label

Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor

@ast

Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor

@en

prefLabel

Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor

@ast

Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor

@en

P1433

Q33597663-406905F5-0F94-4235-8847-31A93A030CF4

P1476

Q33597663-987C0E8B-143E-49E5-B9B2-3779F6292B64

P2093

Q33597663-0532B958-48C0-4869-AA3C-00F443F37F08

Q33597663-0A0732A0-0B6E-478A-A672-31A32D23651F

Q33597663-0E329EB9-037D-4352-8EC8-8B16AD388E7E

Q33597663-1473CB6D-A97D-4005-A80F-9ABB468A4783

Q33597663-1F74155C-D5DD-493F-850F-C57C25ACA872

Q33597663-3EA74E72-A26A-48DD-8573-74CD6212D5DF

Q33597663-5E45E6B3-2BC7-42C4-8A9F-DE460075E247

Q33597663-648D12CE-F0E8-4A55-ACCE-BF242842AFF0

Q33597663-74AF5FBE-6F74-4A53-95C5-4BFD95A68D0E

Q33597663-88A6C197-DAB7-4F3B-8EEA-AA91D3F96064

P2860

Q33597663-011381E6-F6A9-4E7F-90E2-12C5CAF6C1AA

Q33597663-098A1DE0-971B-41D1-B38D-E27015FA4335

Q33597663-17183158-F835-4AD0-90ED-EFAFA68AA226

Q33597663-1C1F3D5B-DC5A-49CC-85BA-70138D5E0883

Q33597663-21FD8B41-DC5B-404D-B97E-931567169CAD

Q33597663-3927BC91-C1B0-410C-9D7C-7C99D3846E4B

Q33597663-3CF6E709-3F66-45B8-8258-BC2792A8AF67

Q33597663-3F7711D5-34EA-4B55-9EC8-D82C6ECFC339

Q33597663-4091CF0B-E339-44E5-A94F-8A2171A83AC7

Q33597663-4495FFD6-B66E-42D3-A5C4-4CF42B7895AC

P2888

Q33597663-9C66B92E-8D89-44D8-8DC7-6AE286019516

P304

Q33597663-76C3B5FF-23C7-4BCB-861E-A4E9609189B6

P31

Q33597663-4A1C23FF-8B40-4DF0-9303-5E1183E77A80

P356

Q33597663-1F611B83-584C-4B70-9455-B570DC44869D

P407

Q33597663-8C4B2351-5886-40E4-A785-D4A2BA53369C

P433

Q33597663-CC16D750-FE55-425A-AA50-054F6913643E

P478

Q33597663-1A5FF201-4BA4-42CC-80D1-9D878768514D

P50

Q33597663-64BBD787-5B17-4933-B2A9-77151690F219

P577

Q33597663-D5431AA3-2C25-446D-89D6-C658D221BD6C

P5875

Q33597663-2C011A6E-C5FF-4FB2-9236-8B592AF49994

P698

Q33597663-BA9D33E2-F27D-4827-BD0C-7A7719983B84

P921

Q33597663-676FFAF0-62FA-4534-B827-7B9BDCCA35C2

P932

Q33597663-B420F4E2-688D-4CC0-8F9D-340B8E480287

P356

P1433

Nature Medicine

P1476

Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor

@en

P2093

Christian Rommel

http://www.w3.org/2001/XMLSchema#string

Collin Vu

http://www.w3.org/2001/XMLSchema#string

David A Fruman

http://www.w3.org/2001/XMLSchema#string

Jing Chen

http://www.w3.org/2001/XMLSchema#string

Jose J Limon

http://www.w3.org/2001/XMLSchema#string

Lomon So

http://www.w3.org/2001/XMLSchema#string

Matthew R Janes

http://www.w3.org/2001/XMLSchema#string

Melissa A Chavez

http://www.w3.org/2001/XMLSchema#string

Michael B Lilly

http://www.w3.org/2001/XMLSchema#string

Michael B Martin

http://www.w3.org/2001/XMLSchema#string

P2860

Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2

mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1)

AKT/PKB signaling: navigating downstream

Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases

Defining the role of mTOR in cancer

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB

The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

P2888

P304

205-213

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NM.2091

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P50

Marina Konopleva

P577

2010-01-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41013406

http://www.w3.org/2001/XMLSchema#string

P698

20072130

http://www.w3.org/2001/XMLSchema#string

P921

P932

4017764

http://www.w3.org/2001/XMLSchema#string